Home > Medical Research Archives > Issue 149 > Breast Cancer Treatment and Antibody Drug Conjugates: Beyond T-DM1
![](https://esmed.org/wp-content/uploads/2022/12/MRA-cover-150x150.png)
Published in the Medical Research Archives
Aug 2021 Issue
Breast Cancer Treatment and Antibody Drug Conjugates: Beyond T-DM1
Published on Aug 11, 2021
DOI
Abstract
Antibody–drug conjugates (ADCs) are a new class of anticancer agents that combine cytotoxic agents attached by a linker to a monoclonal antibody. These engineered drugs can selectively deliver a cytotoxic payload to targeted cancer cells and the local microenvironment (bystander effect), thereby increasing activity and reducing off-target toxicity. The association of ADCs with other anti-cancer therapies is therefore promising.
Trastuzumab-emtansine was the first approved ADC in breast cancer (BC), specifically for the management of human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer. New ADCs are in development in BC. Some have shown meaningful clinical benefit and have been recently approved, such as trastuzumab deruxtecan in HER2-positive trastuzumab emtansine (T-DM1) pretreated BC and Trop-2 guided sacituzumab govitecan in triple-negative BC. Trastuzumab deruxtecan also has potential clinical activity in HER2-low BC thanks to a bystander effect. In this article, we review the ADCs under development in advanced BC.
Author info
Author Area
Have an article to submit?
Submission Guidelines
Submit a manuscript
Become a member